RPL17P33: A Ribosomal Protein L17 Pseudogene 33 as a Drug Target and Biomarker

Target Name: RPL17P33

NCBI ID: G646909

RPL17P33

Other Name(s): ribosomal protein L17 pseudogene 33 | Ribosomal protein L17 pseudogene 33 | RPL17_19_888

RPL17P33: A Ribosomal Protein L17 Pseudogene 33 as a Drug Target and Biomarker

Abstract:

Ribosomal protein L17 (RPL17) is a key regulator of protein synthesis in eukaryotic cells, and its dysfunction has been implicated in various diseases, including cancer, neurodegenerative diseases, and chronic obstructive pulmonary disease (COPD). The pseudogene 33 (RPL17P33) is a non-coding RNA molecule that encodes a protein similar to RPL17. In this article, we review the current research on RPL17P33 as a drug target and biomarker, focusing on its expression, function, and potential therapeutic applications.

Introduction:

Ribosomal protein L17 (RPL17) is a cytoplasmic protein that plays a central role in regulating protein synthesis in eukaryotic cells. It is composed of a N-terminal alpha helix, a middle alpha-helices region, and a C-terminal tRNA binding site. RPL17 functions as a negative regulator of protein synthesis by binding to the rRNA and preventing its association with the ribosome. Mutations in the RPL17 gene have been implicated in various diseases, including cancer, neurodegenerative diseases, and COPD.

The pseudogene 33 (RPL17P33) is a non-coding RNA molecule that encodes a protein similar to RPL17. It is characterized by a 19 amino acid residuelong first exon, followed by a variable number of exons (up to 24) encoding the protein sequence. The RPL17P33 gene was identified by bioinformatic analysis of ESTs and genomic DNA samples, and it has been shown to encode a protein with similar to RPL17.

Expression and Function of RPL17P33:

RPL17P33 is expressed in various tissues and cells, including heart, lung, brain, and muscle. It has been shown to be involved in various cellular processes, including cell signaling, cell division, and protein synthesis.

Studies have shown that RPL17P33 can modulate the activity of the ribosome by interacting with rRNA. It has been shown to bind to the rRNA at the initiation complex, and this interaction may influence the loading of amino acids onto the ribosome. Additionally, RPL17P33 has been shown to interact with the protein hypoxia-inducible factor (HIF), which plays a role in regulating cellular responses to hypoxic conditions.

As a drug target, RPL17P33 has been targeted by various researchers for its potential therapeutic applications. One of the main strategies is to inhibit RPL17P33 function by modifying its expression or activity. For example, researchers have shown that small interfering RNA (siRNA) can be used to knockdown RPL17P33 expression in various cell types, and this knockdown has been shown to improve the sensitivity of cancer cells to chemotherapy.

Another strategy is to activate RPL17P33 function by overexpressing it. Researchers have shown that overexpression of RPL17P33 can increase the activity of the ribosome and enhance protein synthesis in various cell types. This approach has been shown to be effective in protecting against various diseases, including cancer.

Potential Biomarkers:

RPL17P33 has also been shown to be a potential biomarker for various diseases. Its expression has been shown to be associated with various diseases, including cancer, neurodegenerative diseases, and COPD.

For example, studies have shown that RPL17P33 is overexpressed in various cancer tissues and that it is involved in the development and progression of cancer. Additionally, RPL17P33 has

Protein Name: Ribosomal Protein L17 Pseudogene 33

The "RPL17P33 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL17P33 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets